The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

The Fresno County Department of Public Health has confirmed the first pediatric flu and RSV deaths of the 2024-2025 ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

RSV jab slashes hospital admissions by 30% for older people, data suggests - NHS England started rolling out the vaccine for ...

Fresno County health officials have confirmed the first pediatric deaths linked to flu and RSV this season, urging ...

Rising cases of tuberculosis (TB) and measles and an intense influenza and respiratory syncytial virus (RSV) season were seen in England in 2024-25, reiterating the fact that “we cannot be complacent, ...

A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.